Vitamin D for Inflammatory Bowel Disease

In inflammatory bowel disease, vitamin D deficiency is near-universal - and the causation almost certainly runs in both directions.

Fat malabsorption, ileal disease and resection, reduced sun exposure, corticosteroid use and chronic inflammation all lower vitamin D in Crohn's disease and ulcerative colitis. Correcting deficiency is uncontroversial and important, particularly because these patients face substantially elevated osteoporosis risk from disease, steroids and malabsorption combined. The more ambitious claim - that vitamin D modifies disease activity - has genuine mechanistic support and some encouraging small trials, including reduced relapse rates in Crohn's in one randomised study, but has not been established. It remains an adjunct to immunomodulators and biologics, never a substitute.

Inflammatory bowel disease reflects an inappropriate mucosal immune response to commensal bacteria in a genetically susceptible host, with a compromised epithelial barrier. Vitamin D receptors are highly expressed in intestinal epithelium and immune cells, placing calcitriol at the centre of this interaction.

Calcitriol upregulates tight junction proteins, strengthening the barrier, and induces antimicrobial peptides that shape the mucosal microbiota. Immunologically it shifts the balance from Th1 and Th17 responses towards regulatory T cells and reduces pro-inflammatory cytokine production, which is directly relevant to the pathways biologics target. The reverse arm is equally real: inflamed or resected ileum absorbs fat-soluble vitamins poorly, steroids accelerate vitamin D catabolism, and active inflammation lowers circulating levels. Deficiency is therefore both a plausible contributor and a documented consequence.

Requirements in IBD are higher than in the general population, and monitoring is essential.

There are currently no studies linked to this pairing in our library, so no study list is shown.

The high prevalence of deficiency in IBD is thoroughly documented, and gastroenterology guidelines recommend screening and replacement, principally for bone health. Mechanistic work on the vitamin D receptor in intestinal epithelium and mucosal immunity is substantial, and a randomised trial in Crohn's reported reduced relapse rates with supplementation. Disease-modification evidence remains preliminary: trials are small, use varied doses and endpoints, and results are inconsistent. Reverse causation is a serious confounder because inflammation itself lowers vitamin D, and no trial has shown supplementation to induce or maintain remission on its own or to reduce need for immunosuppression.

Vitamin D is well tolerated at the doses used in IBD, though malabsorption means higher doses are often needed to achieve the same level. Monitoring calcium and 25-hydroxyvitamin D avoids the main risk.

Severe flares - frequent bloody stools with fever, tachycardia or abdominal distension - are medical emergencies requiring hospital assessment. Avoid high-dose vitamin D in granulomatous disease and primary hyperparathyroidism, and note that IBD patients also commonly need iron, B12, folate and zinc assessment rather than vitamin D alone.

IBD treatment itself shapes vitamin D requirements.

No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.